US Patent

US11826327 — Treatment for interstitial lung disease

Method of Use · Assigned to United Therapeutics Corp · Expires 2042-02-03 · 16y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

Methods are provided for treating interstitial lung disease by administering treprostinil.

USPTO Abstract

Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3749 — Remodulin
U-3749 — Remodulin
U-3749 — Remodulin
U-3749 — Remodulin
U-3749 — Remodulin
U-3749 — Remodulin

Patent Metadata

Patent number
US11826327
Jurisdiction
US
Classification
Method of Use
Expires
2042-02-03
Drug substance claim
No
Drug product claim
No
Assignee
United Therapeutics Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.